Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Rhea-AI Summary

Teva (NYSE:TEVA) on Jan 27, 2026 announced a partnership with actor and advocate Will Forte to raise awareness of Huntington’s disease (HD) through the Honestly HD program.

The campaign highlights HD symptoms including chorea—involuntary movements affecting up to 90% of people with HD—and directs people to educational resources at HonestlyHD.com. The release notes HD affects more than 41,000 people in the U.S.

News Market Reaction

+1.21%

4 alerts

+1.21% News Effect

-11.2% Trough Tracked

+$446M Valuation Impact

$37.32B Market Cap

16K Volume

On the day this news was published, TEVA gained 1.21%, reflecting a mild positive market reaction. Argus tracked a trough of -11.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $446M to the company's valuation, bringing the market cap to $37.32B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

HD prevalence U.S.: more than 41,000 people HD chorea prevalence: up to 90% Diagnosis year: 2022

3 metrics

HD prevalence U.S. more than 41,000 people People affected by Huntington’s disease in the United States

HD chorea prevalence up to 90% Proportion of people with HD who develop chorea

Diagnosis year 2022 Year Will Forte’s brother-in-law Doug was diagnosed with HD

Market Reality Check

Price: $33.98 Vol: Volume 12,090,889 vs 20-d...

normal vol

$33.98 Last Close

Volume Volume 12,090,889 vs 20-day average 8,736,610 (relative volume 1.38) ahead of this awareness news. normal

Technical Shares trade above the 200-day MA of $20.63 at a price of $32.14, near the 52-week high of $33.42.

Peers on Argus

TEVA was up 1.04% pre-news. Key peers showed mixed but mostly positive moves (e....

TEVA was up 1.04% pre-news. Key peers showed mixed but mostly positive moves (e.g., UTHR +0.83%, RDY +1.25%, TAK +1.16%, VTRS -0.23%), yet no sector-wide momentum was flagged by the scanner.

Previous Partnership Reports

4 past events · Latest: Jun 16 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jun 16	Oncology partnership	Positive	+3.0%	Strategic oncology collaboration on novel anti-PD1-IL2 therapy TEV-56278.
Jan 10	Biosimilar partnership	Positive	-2.6%	Strategic U.S. commercialization deal for EPYSQLI biosimilar with Samsung Bioepis.
Oct 03	Oncology biosimilar deal	Positive	-0.5%	Expansion of mAbxience partnership to include an additional PD-1 oncology biosimilar.
Feb 26	Access partnership	Positive	+3.1%	Partnership with Jiangsu Nhwa to promote patient access to AUSTEDO in China.

Pattern Detected

Partnership headlines have produced mixed reactions, with two clear positive and two negative next-day moves, suggesting no consistent pattern for this tag.

Recent Company History

Over the past year, Teva has repeatedly used partnerships to support its growth strategy. Deals included oncology immunotherapy with Fosun Pharma (Jun 16, 2025), U.S. commercialization of EPYSQLI with Samsung Bioepis (Jan 10, 2025), an expanded oncology biosimilar collaboration with mAbxience (Oct 3, 2024), and a patient-access partnership for AUSTEDO in China with Jiangsu Nhwa (Feb 26, 2024). Today’s awareness-focused partnership continues this collaboration pattern, though with a non-commercial, patient-education angle.

Historical Comparison

+2.3% avg move · Partnership headlines for TEVA have averaged a 2.28% move over 4 events. Today’s patient-awareness c...

partnership

+2.3%

Average Historical Move partnership

Partnership headlines for TEVA have averaged a 2.28% move over 4 events. Today’s patient-awareness collaboration fits the ongoing use of partnerships but leans more toward disease education than direct revenue impact.

Recent partnerships have spanned oncology innovation, biosimilar commercialization, and international access expansion; this HD-focused initiative extends the theme into patient and caregiver education.

Market Pulse Summary

This announcement highlights Teva’s collaboration with Will Forte to increase awareness of Huntingto...

Analysis

This announcement highlights Teva’s collaboration with Will Forte to increase awareness of Huntington’s disease, emphasizing educational resources around HD chorea, which affects up to 90% of patients and more than 41,000 people in the U.S. The news fits a broader pattern of partnerships but is focused on patient support rather than explicit financial terms. Observers may track future HD-related initiatives and how they align with Teva’s broader strategic goals.

Key Terms

chorea, als, parkinson’s, alzheimer’s, +2 more

6 terms

chorea medical

"Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring"

Chorea is a neurological condition that causes sudden, irregular, involuntary movements—like fragments of a dance you can’t control—that can affect the face, limbs, or trunk. It matters to investors because chorea can drive demand for treatments, influence clinical trial design and regulatory decisions, and signal safety or liability risks for companies developing therapies or diagnostics, all of which affect potential market size and financial outlooks.

als medical

"HD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

parkinson’s medical

"often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests"

A progressive neurological condition that damages brain cells controlling movement and other functions, causing tremors, stiffness, slow movement and, over time, cognitive and mood changes; think of it as a gradual failure in the brain’s wiring that affects everyday actions like walking, speaking and eating. Investors track it because the need for better treatments, diagnostics and care creates large, long-term markets and regulatory milestones—like clinical trial results or drug approvals—that can sharply change the value of companies working on therapies, devices, or services for patients.

alzheimer’s medical

"combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive"

A progressive brain disorder that slowly erodes memory, thinking and the ability to perform everyday tasks, often described like a computer whose files and programs are gradually corrupted. It matters to investors because the disease drives demand for diagnostics, treatments and care services, influences regulatory decisions and trial outcomes, and creates large market opportunities as well as high clinical and regulatory risk for companies developing therapies.

neurological disorder medical

"HD, a rare, progressive neurological disorder, affects more than 41,000 people"

A neurological disorder is a condition that affects the brain, spinal cord or nerves, causing problems with movement, thinking, sensation or mood—think of it as a fault in the body’s wiring or software that controls how the body and mind work. Investors care because these disorders drive demand for diagnostics, treatments and long-term care; progress or setbacks in research, approvals and reimbursement can meaningfully change a company’s revenue prospects and the value of related investments.

genetic disorder medical

"HD is a rare, progressive genetic disorder often described as a combination"

A genetic disorder is a health condition caused by changes or errors in a person’s DNA—like a typo in the body’s instruction manual—that can be inherited or occur spontaneously. For investors, these conditions matter because they shape demand for diagnostics, drugs and therapies, influence regulatory hurdles and trial design, and create long-term market opportunities or risks depending on the size of the affected population and the prospects for effective treatments.

AI-generated analysis. Not financial advice.

• Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program
• HD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms¹
• Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,² to help those living with the condition and their care partners better navigate its challenges
  

PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington’s disease (HD). HD, a rare, progressive neurological disorder, affects more than 41,000 people in the U.S. and causes cognitive, behavioral and physical challenges, including HD chorea, which are involuntary movements that often impact daily life.^1,3 As Teva’s new Honestly HD ambassador, Will is sharing his own family’s story with HD to help connect people navigating the disease with educational resources and inspiration.

Will's introduction to the world of HD came through his wife, Olivia. They met when Olivia’s father, Dr. Douglas Modling Jr., was experiencing progression in his HD symptoms and about to enter an assisted living facility for additional care. Her brother, Douglas III (known as Doug), was diagnosed in 2022 and has found comfort in connecting with others living with HD. Inspired by their strength, Will began learning more about the disease, supporting his brother-in-law and joining Olivia’s family in advocating for the HD community.

“Seeing firsthand the challenges my brother-in-law faces, and his enduring hope despite it all, I'm incredibly inspired by the resilience of everyone I’ve met from the HD community. That’s why I’m sharing our story — to help raise awareness of this disease and let people know they are not alone, and that there are resources available to support them," said Will. "It's a hope I share with Teva — that we can empower people with stories like my family’s, or those beginning to experience symptoms like chorea, to connect with resources like Honestly HD and help preserve their independence for as long as possible."

HD is characterized by uncoordinated and uncontrollable movements, cognitive deterioration, and behavioral and/or psychological challenges.¹ About 90% of people with HD will develop chorea, which manifests as involuntary body movements such as fidgeting, squirming or jerking that can affect the hands, face, limbs, torso, speech, and mobility.² While it’s not the only symptom of HD, chorea can have a significant impact on daily activities and progressively limit peoples’ lives, which is why Teva is committed to supporting this community.

“We believe that progress starts with understanding, and that means listening to the real relationships and experiences that define the HD community every day,” said Heather DeMyers, Vice President, U.S. Innovative Medicines Marketing at Teva. “Will and Doug’s story captures the perseverance of so many families impacted by this disease. Their experience is one of inspiration, hope, and the importance of community — embodying the values of Teva’s work with Honestly HD as we strive to bring greater empathy and awareness to those navigating this disease.”

Visit HonestlyHD.com to learn more about HD and hear directly from Will and Doug about their HD story.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

About Chorea Associated with Huntington’s Disease (HD)

Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea – involuntary, random and sudden, twisting and/or writhing movements – is one of the most striking physical manifestations of Huntington’s disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples’ lives.^1,2

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize products for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

1. Huntington’s Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease#toc-what-is-huntington-s-disease-.
2. Thorley, E. M., Iyer, R. G., Wicks, P., Curran, C., Gandhi, S. K., Abler, V., Anderson, K. E., & Carlozzi, N. E. (2018). Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. The patient, 11(5), 547–559. https://doi.org/10.1007/s40271-018-0312-x.
3. Huntington's Disease Society of America. “Overview of Huntington’s Disease.” Hdsa.org, Huntington’s Disease Society of America, 2019, www.hdsa.org/what-is-hd/overview-of-huntingtons-disease/.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
 
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com  

FAQ

What did Teva (TEVA) announce on January 27, 2026 about Huntington’s disease?

Teva announced a partnership with actor Will Forte to promote the Honestly HD program and raise awareness of Huntington’s disease and chorea.

Who is Will Forte and what role does he play in Teva’s Honestly HD program?

Will Forte is the program ambassador sharing his family’s HD story to connect patients and care partners with educational resources and support.

How common is chorea in people with Huntington’s disease according to Teva’s announcement?

The announcement states chorea occurs in about 90% of people with HD and can significantly affect daily activities.

How many people in the U.S. does Teva say are affected by Huntington’s disease?

The announcement cites that HD affects more than 41,000 people in the U.S.

Where can patients and caregivers find Honestly HD resources mentioned by Teva (TEVA)?

Resources and personal stories from Will and others are available at HonestlyHD.com.